Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Bauersachs, Johann [VerfasserIn]   i
 Fraccarollo, D. [VerfasserIn]   i
 Ertl, G. [VerfasserIn]   i
 Gretz, Norbert [VerfasserIn]   i
 Wehling, Martin [VerfasserIn]   i
 Christ, Michael [VerfasserIn]   i
Titel:Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition
Titelzusatz:mechanistic evidence to support RALES
Verf.angabe:J. Bauersachs, D. Fraccarollo, G. Ertl, N. Gretz, M. Wehling, and M. Christ
E-Jahr:2000
Jahr:7 November 2000
Umfang:4 S.
Fussnoten:Gesehen am 28.06.2022
Titel Quelle:Enthalten in: Circulation
Ort Quelle:Philadelphia, Pa. : Lippincott, Williams & Wilkins, 1950
Jahr Quelle:2000
Band/Heft Quelle:102(2000), 19 vom: Nov., Seite 2325-2328
ISSN Quelle:1524-4539
Abstract:Background: A marked reduction of overall mortality in patients with severe congestive heart failure (CHF) has been demonstrated by addition of the mineralocorticoid receptor antagonist spironolactone to ACE inhibition. The aim of the present study was to examine a hypothesized interaction of spironolactone and ACE inhibitors in renal electrolyte and volume regulation. - - Methods and Results: Wistar rats with extensive myocardial infarction or sham operation were treated with either placebo, the ACE inhibitor trandolapril, low-dose spironolactone, or a combination of the 2. Twelve weeks after infarction, rats were housed in metabolic cages. Urinary volume and sodium excretion were significantly increased in CHF rats on a combined treatment with spironolactone and trandolapril (21.2±2.6 mL/d, 2489±320 mmol/d, mean±SD; P<0.05 versus other experimental groups) versus placebo-treated rats (16.7±5.6 mL/d, 1431±458 mmol/d),whereas these parameters were not affected in rats on either spironolactone (16.1±6.6 mL/d, 1153±273 mmol/d) or trandolapril alone (15.9±4.2 mL/d, 1392±294 mmol/d). The effects on natriuresis coincided with a significant reduction of left ventricular end-diastolic pressure (LVEDP) in rats on trandolapril and spironolactone (10.8±8.2 mm Hg; P<0.05 versus CHF placebo: 23.3±7.2 mm Hg; sham-operated rats: 5.1±0.9 mm Hg), whereas LVEDP remained elevated in rats treated with either compound alone. - - Conclusions: In the present study, we found an unexpected interaction of low-dose spironolactone and the ACE inhibitor trandolapril in experimental CHF leading to marked effects on renal electrolyte and volume regulation that were not apparent by treatment with either drug alone. These findings may explain the beneficial effects of spironolactone in CHF patients.
DOI:doi:10.1161/01.CIR.102.19.2325
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1161/01.CIR.102.19.2325
 Volltext: https://www.ahajournals.org/doi/10.1161/01.CIR.102.19.2325
 DOI: https://doi.org/10.1161/01.CIR.102.19.2325
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:angiotensin
 heart failure
 kidney
 myocardial infarction
K10plus-PPN:180802480X
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68935123   QR-Code
zum Seitenanfang